With few real-life studies that have specifically focused on how atopic dermatitis (AD) affects patients living with the ...

Dupilumab in patients with diffuse type 2 CRSwNP had beneficial changes in nasal passage microbiota but did not alter gastrointestinal microbiota.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Introducing lebrikizumab for severe atopic dermatitis in Italy may result in cost savings for the national health system, a ...

When Chloe Tatton boarded a flight to relocate to Dubai early last year, she hoped the change of climate might help ease her ...

Chronic rhinosinusitis with nasal polyps increases the likelihood of developing coexisting conditions, such as asthma, ...

Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...

Patients with AD treated with dupilumab have a lower risk of various infections than those treated with methotrexate or cyclosporine.

Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...

A new international study led by researchers at McMaster University has identified the most effective and safest treatments ...

A new international study led by researchers at McMaster University has identified the most effective and safest treatments ...

The global Biosimilars Market , valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...